First test of new cancer pill halted early
NCT ID NCT04982926
Summary
This was an early safety study of a new oral drug called TAS2940 for people with advanced solid tumors that have specific genetic changes (EGFR or HER2). The main goals were to find a safe dose and see how the body processes the drug. The trial was terminated and enrolled 29 participants who had run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CLCC Gustave Roussy
Villejuif, Cedex, 94805, France
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.